A Randomized Phase III Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer.

Trial Profile

A Randomized Phase III Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2014

At a glance

  • Drugs Capecitabine (Primary) ; Bevacizumab; Docetaxel; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms TABEA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Jun 2013 Interim results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Oct 2012 Status changed from recruiting to discontinued as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top